$ASMB
Assembly Biosciences Inc

2012 Q2 Form 10-Q Financial Statement

#000114420412027148 Filed on May 09, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2012 Q1 2011 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.320M $1.770M $1.700M
YoY Change -65.26% 4.12% 4150.0%
% of Gross Profit
Research & Development $6.162M $6.423M $970.8K
YoY Change 98.8% 561.62% 136.77%
% of Gross Profit
Depreciation & Amortization $0.00 $997.00 $755.00
YoY Change 32.05%
% of Gross Profit
Operating Expenses $6.162M $6.423M $970.8K
YoY Change 98.8% 561.62% 115.72%
Operating Profit -$7.478M -$8.190M -$2.667M
YoY Change 8.36% 207.11%
Interest Expense $10.00K $20.00K $44.66K
YoY Change -84.83% -55.22% -102.84%
% of Operating Profit
Other Income/Expense, Net $0.00 -$69.18K
YoY Change
Pretax Income -$7.470M -$8.170M -$2.720M
YoY Change 7.33% 200.37% 34.65%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.470M -$8.174M -$2.722M
YoY Change 7.3% 200.24% 34.78%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.953M -$3.294M -$1.902M
COMMON SHARES
Basic Shares Outstanding 12.49M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q2 2012 Q1 2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.80M $31.10M $14.00M
YoY Change 152.63% 122.14%
Cash & Equivalents $28.84M $31.07M $14.00M
Short-Term Investments
Other Short-Term Assets $157.1K $316.3K $100.0K
YoY Change 57.09% 216.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $29.00M $31.38M $14.10M
YoY Change 152.18% 122.57%
LONG-TERM ASSETS
Property, Plant & Equipment $9.375K $7.221K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $9.375K $7.221K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $29.00M $31.38M $14.10M
Total Long-Term Assets $9.375K $7.221K $0.00
Total Assets $29.01M $31.39M $14.10M
YoY Change 152.26% 122.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.158M $3.143M $100.0K
YoY Change 426.31% 3042.86%
Accrued Expenses $234.0K $710.0K $200.0K
YoY Change 134.0% 255.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.392M $3.853M $300.0K
YoY Change 323.98% 1184.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $1.300M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $1.300M
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.392M $3.853M $300.0K
Total Long-Term Liabilities $0.00 $0.00 $1.300M
Total Liabilities $3.400M $3.900M $1.600M
YoY Change 61.9% 143.75%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $12.92K $12.44K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.62M $27.54M $12.50M
YoY Change
Total Liabilities & Shareholders Equity $29.01M $31.39M $14.10M
YoY Change 152.26% 122.63%

Cashflow Statement

Concept 2012 Q2 2012 Q1 2011 Q1
OPERATING ACTIVITIES
Net Income -$7.470M -$8.174M -$2.722M
YoY Change 7.3% 200.24% 34.78%
Depreciation, Depletion And Amortization $0.00 $997.00 $755.00
YoY Change 32.05%
Cash From Operating Activities -$6.940M -$6.090M -$1.815M
YoY Change 142.66% 235.52% 1.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $11.96K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$11.96K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.166M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.720M 180.7K 1.256M
YoY Change 2045.45% -85.62% -54.81%
NET CHANGE
Cash From Operating Activities -6.940M -6.090M -1.815M
Cash From Investing Activities 0.000 0.000 -11.96K
Cash From Financing Activities 4.720M 180.7K 1.256M
Net Change In Cash -2.220M -5.909M -570.5K
YoY Change -15.91% 935.67% -157.63%
FREE CASH FLOW
Cash From Operating Activities -$6.940M -$6.090M -$1.815M
Capital Expenditures $0.00 $0.00 $11.96K
Free Cash Flow -$6.940M -$6.090M -$1.827M
YoY Change 142.66% 233.32% 2.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12486313 shares
CY2011Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14000524
CY2012Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3852858
CY2012Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
709995
CY2012Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q1 us-gaap Assets
Assets
31390174
CY2012Q1 us-gaap Common Stock Value
CommonStockValue
12444
CY2012Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12444646 shares
CY2012Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q1 us-gaap Assets Current
AssetsCurrent
31382953
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14571055
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2513074
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
171000
CY2011Q4 us-gaap Assets
Assets
37045781
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
12406
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12406406 shares
CY2012Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
75702960
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31066611
CY2012Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103227832
CY2012Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31390174
CY2012Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q1 us-gaap Stockholders Equity
StockholdersEquity
27537316
CY2012Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12444646 shares
CY2012Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7221
CY2012Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2012Q1 us-gaap Other Assets Current
OtherAssetsCurrent
316342
CY2012Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3142863
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Assets Current
AssetsCurrent
37037563
CY2011Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
67529084
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36975434
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102049385
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37045781
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
34532707
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12406406 shares
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8218
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
62129
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2342074
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
4684
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
419380
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
258453
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1146024
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39224
us-gaap Investment Income Interest
InvestmentIncomeInterest
112234
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
419380
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
57889
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1431603
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
527349
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46527850
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2865758
us-gaap Share Based Compensation
ShareBasedCompensation
6654626
us-gaap Depreciation
Depreciation
32003
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3852858
us-gaap Interest Expense
InterestExpense
4983572
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
65173167
us-gaap Other Noncash Expense
OtherNoncashExpense
227910
us-gaap Net Income Loss
NetIncomeLoss
-75702960
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13754773
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45951969
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
800000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
6001496
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39224
us-gaap Operating Income Loss
OperatingIncomeLoss
-61964368
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31066611
us-gaap Interest Paid
InterestPaid
685397
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1087876
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16012399
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3466010
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77633685
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
800000
vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
341334
vtus Supplemental Warrant Issued In Connection With Short Term Borrowings
SupplementalWarrantIssuedInConnectionWithShortTermBorrowings
1166989
CY2011Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
419380
CY2011Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
82618
CY2011Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11963
CY2011Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13490
CY2011Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
55004
CY2011Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1814967
CY2011Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
24513
CY2011Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1005542
CY2011Q1 us-gaap Depreciation
Depreciation
755
CY2011Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-189999
CY2011Q1 us-gaap Interest Expense
InterestExpense
44663
CY2011Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
2420775
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-2722478
CY2011Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-69176
CY2011Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
970762
CY2011Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
800000
CY2011Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11963
CY2011Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2666792
CY2011Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-570531
CY2011Q1 us-gaap Interest Paid
InterestPaid
39325
CY2011Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1696030
CY2011Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1256399
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2011Q1 vtus Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
7147624 shares
CY2012Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2012Q1 dei Trading Symbol
TradingSymbol
VTUS
CY2012Q1 dei Entity Registrant Name
EntityRegistrantName
VENTRUS BIOSCIENCES INC
CY2012Q1 dei Amendment Flag
AmendmentFlag
false
CY2012Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012Q1 dei Document Type
DocumentType
10-Q
CY2012Q1 dei Document Period End Date
DocumentPeriodEndDate
2012-03-31
CY2012Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001426800
CY2012Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
714355
CY2012Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
225513
CY2012Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
196324
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
16181
CY2012Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
57889
CY2012Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
238617
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6089551
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
714355
CY2012Q1 us-gaap Depreciation
Depreciation
997
CY2012Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1339784
CY2012Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
238617
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-8173876
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6422726
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2012Q1 vtus Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
12408927 shares
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8190057
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5908823
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1767331
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
180728

Files In Submission

Name View Source Status
0001144204-12-027148-index-headers.html Edgar Link pending
0001144204-12-027148-index.html Edgar Link pending
0001144204-12-027148.txt Edgar Link pending
0001144204-12-027148-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v311572_10q.htm Edgar Link pending
v311572_ex31-1.htm Edgar Link pending
v311572_ex31-2.htm Edgar Link pending
v311572_ex32-1.htm Edgar Link pending
v311572_ex32-2.htm Edgar Link pending
vtus-20120331.xml Edgar Link completed
vtus-20120331.xsd Edgar Link pending
vtus-20120331_cal.xml Edgar Link unprocessable
vtus-20120331_def.xml Edgar Link unprocessable
vtus-20120331_lab.xml Edgar Link unprocessable
vtus-20120331_pre.xml Edgar Link unprocessable